News Conference News AHA 2024 Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360 Michael O'Riordan November 18, 2024
News Conference News AHA 2024 GLORIOUS: Neither Exenatide Nor Restrictive Oxygenation Boost CV Surgery Outcomes Michael O'Riordan November 17, 2024
News Conference News AHA 2024 Audits and Feedback Aid Pharmacist-Driven HF Care: PHARM-HF A&F Michael O'Riordan November 16, 2024
News Conference News AHA 2024 SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity Michael O'Riordan November 16, 2024
News Conference News AHA 2024 US Obesity Epidemic Continues to Skyrocket, With No End in Sight Michael O'Riordan November 15, 2024
News Daily News Many Patients Quit Taking GLP-1 Drugs: Understanding Why Is Key Todd Neale November 13, 2024
News Daily News High Lp(a) Linked to ASCVD Risk Even When LDL Cholesterol Is Low Michael O'Riordan November 13, 2024
News Daily News Hypertensive Disorders of Pregnancy Lead to Earlier, More Severe CAD Caitlin E. Cox November 12, 2024
News Daily News IVC Filter Use Declining, but Retrieval Rates Abysmally Low: SAFE-IVC Michael O'Riordan November 11, 2024
News Daily News Coronary CTA Reimbursement for US Hospitals to Double in 2025 Yael L. Maxwell November 08, 2024
News Daily News FDA Approves Varipulse Pulsed-Field Ablation System for AF Michael O'Riordan November 07, 2024
News Daily News Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data Michael O'Riordan November 07, 2024
News Conference News TCT 2024 Co-STAR Hints That Colchicine May Curb Rhythm Disturbances After TAVI Michael O'Riordan November 06, 2024
Podcast Heart Valve Matters Ethics of AI Detection of Subclinical Disease with Michael Mack November 01, 2024
Podcast Heart Valve Matters Economics of AI Detection of Subclinical Disease with Michael Mack November 01, 2024
News Conference News TCT 2024 TRISCEND II: Full Results a Win for TTVR in Severe Tricuspid Regurgitation Michael O'Riordan October 30, 2024
News Conference News TCT 2024 ACURATE IDE Trial Misses Primary Endpoint in All-Risk TAVI Patients Todd Neale October 30, 2024
Presentation TCT 2024 One-year Outcomes of ACURATE neo2 vs Approved TAVR Devices in All-risk patients with Severe AS: the ACURATE IDE Trial Presenter: Michael Reardon October 30, 2024
Presentation TCT 2024 TCT 918: Association of TVT Site Risk Adjusted Stroke Rates and Joint Commission Stroke Certification Designation Level Presenter: G. Michael Deeb October 30, 2024